VA-INTELSAT
23.5.2024 15:31:29 CEST | Business Wire | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of inflight connectivity (IFC), will deliver years of additional reliable broadband, video distribution and mobile satellite service to customers across three continents thanks to the success of Northrop Grumman’s innovative Mission Extension Vehicle (MEV) that will ultimately provide an expected additional nine years of life to the Intelsat 10-02 (IS-10-02) geosynchronous satellite.
Geosynchronous Earth orbit (GEO) satellites have an average lifespan of about 15-20 years before they start running low on fuel. Intelsat in 2020 became the first satellite operator to commit to deploying two of Northrop Grumman’s MEVs to extend the life of an otherwise healthy satellite. Both MEVs have been successful at their mission and have allowed IS-10-02 and Intelsat 901 (IS-901) to provide five years of service beyond the expected lifespan of the satellite. Under amendments to the original agreements with Northrop Grumman’s SpaceLogistics LLC, both MEVs will stay in space serving Intelsat satellites for several more years, allowing them to operate longer.
- At the end of the current servicing period, MEV-1 will release the IS-901 satellite into the GEO graveyard and then provide service for another Intelsat satellite.
- MEV-2 will remain docked to Intelsat’s current vehicle, IS-10-02, providing life-extension for several years – nearly doubling service from the original contract. The IS-10-02 satellite was manufactured by Airbus Defense & Space, was launched in June 2004 and entered service in August 2004. Capacity on the satellite is shared with Telenor Satellite. Today, MEV-2 is helping to extend the life of IS-10-02, so the satellite can continue providing high-quality media distribution and broadband services to our customers across Europe, the Middle East, Africa and South America. IS-10-02 is a key satellite in the Intelsat-Telenor Satellite video neighborhood, distributing more than 900 channels to nearly 18 million television households across Europe.
“As the largest satellite operator in geosynchronous orbit, Intelsat has always been committed to continuous reliable service, as well as leadership in furthering sustainable space operations,” said Jean-Luc Froeliger, SVP Space Systems at Intelsat. “Intelsat continues to pursue first-of-their-kind innovations to extend the life of its satellites in orbit, while also bringing the industry together to foster information sharing and collaboration across a challenging regulatory environment to achieve sustainable stewardship of the resource of space.”
“This extension is excellent news for our many clients across Europe and the Middle East who are served by THOR 10-02,” said Morten Tengs, CEO of Telenor Satellite. “We pride ourselves on the resilience of our service and, by extending the life of the satellite, we can ensure continuity and hassle-free operations for a number of years.”
MEV Background
In 2020, MEV-1 successfully docked with the IS-901 satellite, a high-performing satellite that was running low on fuel. That marked the first time that two commercial spacecraft docked and began mission-extension service in GEO. The in-space maneuver pointed IS-901 to targeted antennas on Earth and extended its life for another five years of its lifespan.
In 2021, the feat was repeated with a second MEV-2 docking with the IS-10-02 satellite. Unlike the first docking, which was performed in a graveyard orbit a few hundred kilometers above active satellites, this time the MEV-2 docked with IS-10-02 in its original orbital slot and avoided any interruption of services to customers, resulting in the first-ever in-orbit servicing of a live commercial satellite in GEO.
About Intelsat
Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.
Follow Us on Social Media:
X | LinkedIn | Instagram | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523619448/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
